Topics

Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years

04:26 EST 8 Nov 2019 | Pharmaceutical Business Review

Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages four to 16 years. Vaccine efficacy (VE) was 80.2% (95% confidence

The post Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years appeared first on Pharmaceutical Business review.

Original Article: Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years

NEXT ARTICLE

More From BioPortfolio on "Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years"

Quick Search

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...